Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent chemoradiotherapy after induction pemetrexed + cisplatin versus paclitaxel + cisplatin in stage IIIA/IIIB NSCLC
ChiCTR-IPR-15006245Phase 4Not yet recruiting
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pemetrexed, cisplatin and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoints: Local control rate, Progression-free survival and 1 more. Planned start Jun 2015; status: not yet recruiting.
02
Drugs
pemetrexedcisplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-15006245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006245.